AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $3.00, $0.08 better than the analyst estimate of $2.92. Revenue for the quarter came in at $14.46 billion versus the consensus estimate of $14.28 billion.

GUIDANCE:

AbbVie sees FY2024 EPS of $10.90-$10.94, versus the consensus of $10.85.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Benchmark Starts Boyd Gaming (BYD) at Buy
• Western Midstream Partners, LP (WES) files for share and debt offering
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion